PIEDMONT ANGEL NETWORK LLC The Entrepreneurs Fund SM September 2007 | Press Release: The Piedmont Angel Network Two announced its lead investment in a $500,000 Series B Convertible Note in Bioptigen. The Durham-based company's technology provides a platform that enables non-invasive, real-time two- and three-dimensional imaging of the eye with resolution 100 times finer than ultrasound, and twice as fine as previous generation OCT technology. Bioptigen SDOCT imaging systems provide unmatched image quality and system versatility for monitoring the progression of eye disease from the very earliest stages. The company is initially targeting advanced diagnostics and research of age-related macular degeneration and glaucoma with tools that image both human and animal subjects. September 27 | Register for SBTDC's Power of Angel Investing Seminar on October 19-20 in Boone, North Carolina. September 21 | Piedmont Angel Network announces member meeting and screening meeting dates for next twelve months. August 23 | Wake Forest University Academic Symposia on Biotechnology: Innovation, Funding & Ethics. Scheduled for Friday, September 29. August 11 | PAN Two announces first investment in Bioptigen. July 31 | PAN Two is searching for a permanent Fund Executive.
Piedmont Angel Network | TheEntrepreneur'sFund
September 2007 | Press Release: The Piedmont Angel Network Two announced its lead investment in a $500,000 Series B Convertible Note in Bioptigen. The Durham-based company's technology provides a platform that enables non-invasive, real-time two- and three-dimensional imaging of the eye with resolution 100 times finer than ultrasound, and twice as fine as previous generation OCT technology. Bioptigen SDOCT imaging systems provide unmatched image quality and system versatility for monitoring the progression of eye disease from the very earliest stages. The company is initially targeting advanced diagnostics and research of age-related macular degeneration and glaucoma with tools that image both human and animal subjects.